Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. The unique information we provide fuels development of new diagnostics, vaccines, and therapeutics. Founded in 2014, and backed by investors including Illumina Ventures, LabCorp, and Merck, Serimmune is developing new approaches for preventing, diagnosing, and treating a range of diseases.
Location: United States, California, Goleta
Employees: 11-50
Total raised: $21.4M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Illumina V... | illuminaVe... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.09.2020 | - | $12M | - |
| 10.06.2019 | - | $1.4M | - |
| 20.06.2017 | - | $8M | - |
Mentions in press and media 14
| Date | Title | Description |
| 24.09.2021 | StartUPDATES: New developments from healthcare startups | Serimmune and Mymee announced this week that they will collaborate on a clinical research study to describe the role antibodies play in patients suffering from COVID-19. The partnership includes collaborating on research to understand the p... |
| 30.07.2021 | StartUPDATES: New developments from healthcare startups | Serimmune has added Rocco R. Raduazo to their leadership team as the VP of Business Development. Rocco joins Serimmune with a primary role of building the Serimmune Research Services arm. He will drive strategic partnership opportunities wi... |
| 16.04.2021 | StartUPDATES: New developments for healthcare startups | Serimmune, Inc., a leader in understanding the functional antibody repertoire’s role in human disease, announced this week that the company is enrolling 2,000 research participants in a study designed to understand the human immune response... |
| 12.03.2021 | Serimmune launches new immune response mapping service for COVID-19 | Immune intelligence startup Serimmune hopes to better understand the relationship between antibody epitopes (the parts of antigen molecules that bind to antibodies) and the SARS-CoV-2 virus. The company’s proprietary technology, originally ... |
| 12.03.2021 | StartUPDATES: New developments for healthcare startups | Serimmune, a leader in understanding the functional antibody repertoire’s role in human disease, this week launched a Covid antibody epitope mapping discovery service. This offering now provides academic and biopharma researchers with ready... |
| 05.05.2020 | LetsGetChecked raises $71 million as COVID-19 epidemic makes home testing increasingly vital | As the country wrestles with the COVID-19 epidemic, home health testing, checkups and diagnostics have never been more important and companies like LetsGetChecked are filling a void left in a U.S. healthcare system consumed by the outbreak.... |
| 10.06.2019 | SerImmune Finds $1.4M In Ongoing Funding | Santa Barbara-based SerImmune, a company developing immune mapping technology, has raised $1.4M in new funding, as part of what appears to be an ongoing $7.0M funding effort. The funding--which was disclosed via a regulatory filing--shows t... |
| 21.06.2017 | SerImmune Raises $8M | SANTA BARBARA, CA, SerImmune Inc. today announced an $8 million round of financing, led by Illumina Ventures. >> Click here for more funding data on SerImmune >> To export SerImmune funding data to PDF and Excel, click here ... |
| 21.06.2017 | SerImmune Scores $8M For Antibody Mapping | Santa Barbara-based SerImmune, a developer of immune mapping technology, has raised $8M in a funding round to map out the human immune systems, according to the company. The funding was led by Illumina Ventures, and also included Merck and ... |
| 20.06.2017 | SerImmune Raises $8M in Funding | SerImmune Inc., a Santa Barbara, Calif.-based provider of a platform that maps circulating antibodies to their diverse antigens using molecular libraries composed of billions of antigen decoys and big data informatic tools, raised $8m in fu... |
Show more